<SEC-DOCUMENT>0001193125-19-085283.txt : 20190325
<SEC-HEADER>0001193125-19-085283.hdr.sgml : 20190325
<ACCEPTANCE-DATETIME>20190325161433
ACCESSION NUMBER:		0001193125-19-085283
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190321
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190325
DATE AS OF CHANGE:		20190325

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		19702815

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d683164d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;21, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Pharmaceuticals, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-14888</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">33-0969592</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>660 W. Germantown Pike, Suite 110 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Plymouth Meeting, PA 19462 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(267) <FONT STYLE="white-space:nowrap">440-4200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or
former address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp; &#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;21, 2019, the Board of Directors (the &#147;Board&#148;) of Inovio Pharmaceuticals, Inc. (the &#147;Company&#148;)
appointed Ann C. Miller, M.D. to serve as a director of the Company. Dr.&nbsp;Miller&#146;s term will continue until the Company&#146;s 2019 Annual Meeting of Stockholders. There is no arrangement or understanding between Dr.&nbsp;Miller and any
other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Dr.&nbsp;Miller and any of the Company&#146;s other directors or executive officers. The Company is not aware of any
transaction involving Dr.&nbsp;Miller requiring disclosure under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> Additional information regarding Dr.&nbsp;Miller is set forth below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ann C. Miller, M.D., age 62, joined the Board in March 2019. Dr.&nbsp;Miller worked at Sanofi S.A. from 2012 until her retirement in September 2018, serving
as Vice President of Marketing and Vice President of Global Marketing, Oncology Division. From 2009 to 2011, Dr.&nbsp;Miller served as Senior Vice President of Pharmaceutical Services at Eisai Co., Ltd., leading its Primary Care and Specialty
Business unit. Dr.&nbsp;Miller previously served in management roles in global marketing at Amgen Inc. and in positions of increasing responsibility at Merck&nbsp;&amp; Co., Inc. over a period of 16 years. Dr.&nbsp;Miller received an M.D. from the
Duke University School of Medicine and a B.A. in chemistry with honors from Duke University. She is a member of the Duke University Medical Alumni Council. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Miller will be compensated in accordance with the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy.
She will receive an annual cash retainer of $45,000 for serving on the Board. In addition, Dr.&nbsp;Miller received initial equity awards under and pursuant to the Company&#146;s 2016 Omnibus Incentive Plan upon her appointment as of March&nbsp;21,
2019, the date of grant. As a newly elected director, Dr.&nbsp;Miller was awarded 12,821 restricted stock units and a stock option to purchase 20,000 shares of the Company&#146;s common stock at an exercise price of $3.72, the closing price of the
Company&#146;s common stock on the date of grant. The restricted stock units will vest over a period of three years, with <FONT STYLE="white-space:nowrap">one-third</FONT> of the shares vesting on each of the first, second and third anniversaries of
the grant date, subject to Dr.&nbsp;Miller&#146;s continued service as a director of the Company as of each vesting date. With respect to the shares of common stock underlying the stock option grant,
<FONT STYLE="white-space:nowrap">one-quarter</FONT> of the shares vested as of the grant date, with the remainder vesting in three equal annual installments on the first, second and third anniversaries of the grant date, subject to
Dr.&nbsp;Miller&#146;s continued service as a director of the Company as of each vesting date. Dr.&nbsp;Miller will be eligible to receive additional annual equity awards on each date of the Company&#146;s annual meeting of stockholders in
accordance with the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;25, 2019, the Company issued a press release announcing the appointment of Dr.&nbsp;Miller to the Board. A copy of this press release is
furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
amended (the &#147;Exchange Act&#148;), and is not incorporated by reference into any of the Company&#146;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be
expressly set forth by specific reference in any such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="d683164dex991.htm">Press Release, dated March&nbsp;25, 2019. </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>INOVIO PHARMACEUTICALS, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;25, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Kies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d683164dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g683164g0325061607604.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>CONTACTS:</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investors:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Ben Matone, Inovio, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">484-362-0076,</FONT></FONT> <U>ben.matone@inovio.com</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Media:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Jeff Richardson, Inovio, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">267-440-4211,</FONT></FONT> <U>jrichardson@inovio.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Inovio Appoints Global Commercial Leader </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>to its Board of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH
MEETING, PA &#150; March&nbsp;25, 2019 &#150; Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the appointment of Dr.&nbsp;Ann&nbsp;C. Miller to its Board of Directors. Dr.&nbsp;Miller had an outstanding marketing career launching and
building blockbuster products for Merck, Amgen, Eisai and Sanofi. While at Sanofi, she led the Sanofi Oncology Global Marketing function including its pipeline, launch, and life cycle management activities. Prior to Sanofi, Dr.&nbsp;Miller served as
Senior Vice President at Eisai, including leading the Primary Care and Specialty Business unit with the blockbusters Aricept<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and
Aciphex<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and the enterprise-wide service platform for the Oncology and Primary Care businesses. At Amgen, Dr.&nbsp;Miller contributed to building the Global Marketing function; as Executive
Director, Global Marketing, Oncology Therapeutic Area she provided commercialization and life cycle management oversight for key products including Neulasta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Vectibix<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. During her <FONT STYLE="white-space:nowrap">16-year</FONT> career at Merck&nbsp;&amp; Co. she held numerous positions of increasing responsibility including brand lead for such billion-dollar
products as Fosamax<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Mevacor<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and Zocor<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. Dr.&nbsp;Miller holds MD and BA
degrees with honors from Duke University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;J. Joseph Kim, President and CEO, said, &#147;Dr.&nbsp;Miller&#146;s expertise will help guide us as
we transition to a commercial organization. We will benefit from her clinical training and extensive experience developing and executing launch and growth strategies across a wide range of oncology, specialty and primary care portfolios and
products.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is in late-stage development for several of its product candidates. Inovio&#146;s lead product,
<FONT STYLE="white-space:nowrap">VGX-3100,</FONT> for <FONT STYLE="white-space:nowrap">HPV-caused</FONT> cervical dysplasia, is advancing in global Phase 3 trials. Inovio is developing its HPV program in Phase 2 trials treating <FONT
STYLE="white-space:nowrap">HPV-caused</FONT> vulvar and anal dysplasia. Inovio&#146;s technology platform is demonstrating its versatility in two Phase 2 oncology combination trials integrating Inovio&#146;s
<FONT STYLE="white-space:nowrap">INO-5401</FONT> therapy with several checkpoint inhibitors from Genentech/Roche (for bladder cancer,) and Regeneron (for brain cancer (GBM)). MEDI0457 <FONT STYLE="white-space:nowrap">(VGX-3100</FONT> + <FONT
STYLE="white-space:nowrap">pIL-12,</FONT> which Inovio licensed to AstraZeneca) is in Phase 2 combination trials with durvalumab targeting head&nbsp;&amp; neck cancer and cervical cancer in addition to a broad array of other cancers associated with
the human papilloma virus. Inovio&#146;s infectious disease pipeline is also moving vaccines into late-stage trials for Lassa fever, Ebola, MERS and HIV. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Inovio Pharmaceuticals, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inovio is a
late-stage biotechnology company focused on the discovery, development, and commercialization of <FONT STYLE="white-space:nowrap">DNA-based</FONT> immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious
disease.&nbsp;Inovio&#146;s proprietary technology platform applies antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases.&nbsp;The technology functions exclusively <I>in vivo</I>, and has been demonstrated to
consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. Inovio&#146;s most advanced clinical program, <FONT STYLE="white-space:nowrap">VGX-3100,</FONT> is in Phase 3 for the treatment
of <FONT STYLE="white-space:nowrap">HPV-related</FONT> cervical <FONT STYLE="white-space:nowrap">pre-cancer.&nbsp;Also</FONT> in development are Phase 2 immuno-oncology programs targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> cancers,
bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV.&nbsp;Partners and collaborators include AstraZeneca, Regeneron, Roche/Genentech, ApolloBio Corporation, The Wistar Institute, The
Bill&nbsp;&amp; Melinda Gates Foundation, the University of Pennsylvania, </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Parker Institute for Cancer Immunotherapy, CEPI, DARPA, GeneOne Life Science, Plumbline Life Sciences, NIH, HIV Vaccines Trial Network, National Cancer Institute, Walter Reed Army Institute of
Research, Drexel University, and Laval University.&nbsp;For more information, visit <U>www.inovio.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene
delivery technologies and DNA vaccines, our expectations regarding our research and development programs, including the planned initiation and conduct of clinical trials and the availability and timing of data from those trials. Actual events or
results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials and product development programs, the
availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our pipeline of SynCon<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> active immunotherapy and vaccine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may
be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful
protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote
other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the
impact of government healthcare proposals and other factors set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2018 and other regulatory filings we make from time to time. There
can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that final results of clinical trials will be supportive of regulatory approvals required to market licensed products, or
that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required
by law. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g683164g0325061607604.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g683164g0325061607604.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 1\# 2(  A$! Q$!_\0
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M1V=OKG']*\1UO3I-)UJ[L9%*F*0@9[CL?RKUOX2ZNESH4VFLP\ZW?<!ZJ?\
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M;HD_]\K7H]>%?"SQ%'I&NO8W+A+>] 4,3P''3\\D?E7NM !1110!S/Q!=(_
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2V$'[QAAYGY=_Q]/85M4@/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
